LGND compared with SUPN: revenue, margins and what each company keeps, and the suppliers and customers both name

LGNDLigand Pharmaceuticals Inc

Mkt capRevenueRevenue

SUPNSupernus Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

LGNDLigand Pharmaceuticals Inc

SUPNSupernus Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LGND

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±7.5%▼−0.45%×0.07

Q2 FY26±7.1%▼−0.80%×0.11

May 7 '26±6.2%▼−9.55%×1.55

Q1 FY26±7.8%▲+2.50%×0.32

SUPN

0 of 2at or beyond implied

Reportimpliedrealized× implied

Oct 30 '26—▲+0.19%—

Q3 FY26—▲+3.49%—

= impliedLGND realized, solidSUPN realized, hatchedOne scale, both sides: full bar = 12%× = |realized| ÷ impliedspan: LGND 245d · SUPN 99dSource: market data

Aug 3 '26

±11.3%

▲+3.07%

×0.27

Q2 FY26±11.3%▲+0.53%×0.04

LGNDLigand Pharmaceuticals Inc

306.27▲+2.43%· post 308.00

Mkt cap$6.1BRevenue$79MQ3 FY26Revenue$268MFY25

SUPNSupernus Pharmaceuticals, Inc.

26.15▼−2.21%· post 26.15

ClosedNov 6 '26

Mkt cap$3.1BRevenue$356MQ3 FY26Revenue$719MFY25

Compare

ClosedNov 6 '26

LGNDLigand Pharmaceuticals Inc

SUPNSupernus Pharmaceuticals, Inc.

306.27▲+2.43%post 308.00

Price

26.15▼−2.21%post 26.15

$6.1B

Mkt cap

$3.1B

Q3 FY26$79M

Revenue

$356MQ3 FY26

FY25$268M

Revenue

$719MFY25

LGND306.27▲+2.43%vsSUPN26.15▼−2.21%ClosedNov 6 '26